Literature DB >> 26173433

YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors.

Patricia Marti1, Claudia Stein1, Tanja Blumer2, Yann Abraham1, Michael T Dill2, Monika Pikiolek1, Vanessa Orsini1, Giorgia Jurisic1, Philippe Megel3, Zuzanna Makowska2, Claudia Agarinis1, Luigi Tornillo4, Tewis Bouwmeester1, Heinz Ruffner1, Andreas Bauer1, Christian N Parker1, Tobias Schmelzle3, Luigi M Terracciano4, Markus H Heim2, Jan S Tchorz1.   

Abstract

UNLABELLED: The Yes-associated protein (YAP)/Hippo pathway has been implicated in tissue development, regeneration, and tumorigenesis. However, its role in cholangiocarcinoma (CC) is not established. We show that YAP activation is a common feature in CC patient biopsies and human CC cell lines. Using microarray expression profiling of CC cells with overexpressed or down-regulated YAP, we show that YAP regulates genes involved in proliferation, apoptosis, and angiogenesis. YAP activity promotes CC growth in vitro and in vivo by functionally interacting with TEAD transcription factors (TEADs). YAP activity together with TEADs prevents apoptosis induced by cytotoxic drugs, whereas YAP knockdown sensitizes CC cells to drug-induced apoptosis. We further show that the proangiogenic microfibrillar-associated protein 5 (MFAP5) is a direct transcriptional target of YAP/TEAD in CC cells and that secreted MFAP5 promotes tube formation of human microvascular endothelial cells. High YAP activity in human CC xenografts and clinical samples correlates with increased MFAP5 expression and CD31(+) vasculature.
CONCLUSIONS: These findings establish YAP as a key regulator of proliferation and antiapoptotic mechanisms in CC and provide first evidence that YAP promotes angiogenesis by regulating the expression of secreted proangiogenic proteins.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26173433     DOI: 10.1002/hep.27992

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  97 in total

1.  Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.

Authors:  Shanshan Zhang; Xinhua Song; Dan Cao; Zhong Xu; Biao Fan; Li Che; Junjie Hu; Bin Chen; Mingjie Dong; Maria G Pilo; Antonio Cigliano; Katja Evert; Silvia Ribback; Frank Dombrowski; Rosa M Pascale; Antonio Cossu; Gianpaolo Vidili; Alberto Porcu; Maria M Simile; Giovanni M Pes; Gianluigi Giannelli; John Gordan; Lixin Wei; Matthias Evert; Wenming Cong; Diego F Calvisi; Xin Chen
Journal:  J Hepatol       Date:  2017-07-19       Impact factor: 25.083

2.  The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies.

Authors:  Nathan Werneburg; Gregory J Gores; Rory L Smoot
Journal:  Gene Expr       Date:  2019-06-28

3.  The cytoprotective impact of yes-associated protein 1 after ischemia-reperfusion injury in AC16 human cardiomyocytes.

Authors:  Kashif Khan; Georges Makhoul; Bin Yu; Adel Schwertani; Renzo Cecere
Journal:  Exp Biol Med (Maywood)       Date:  2019-05-29

Review 4.  Emerging concepts in biliary repair and fibrosis.

Authors:  Luca Fabris; Carlo Spirli; Massimiliano Cadamuro; Romina Fiorotto; Mario Strazzabosco
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-05-19       Impact factor: 4.052

5.  TAZ responds to fluid shear stress to regulate the cell cycle.

Authors:  Hyun Jung Lee; Adesuwa Ewere; Miguel F Diaz; Pamela L Wenzel
Journal:  Cell Cycle       Date:  2018-01-18       Impact factor: 4.534

6.  The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.

Authors:  Ayumi Kaneda; Toshihiro Seike; Tomohiro Danjo; Takahiro Nakajima; Nobumasa Otsubo; Daisuke Yamaguchi; Yoshiro Tsuji; Kaori Hamaguchi; Mai Yasunaga; Yoichi Nishiya; Michihiko Suzuki; Jun-Ichi Saito; Rie Yatsunami; Satoshi Nakamura; Yoshitaka Sekido; Kiyotoshi Mori
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

7.  The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma.

Authors:  EeeLN H Buckarma; Nathan W Werneburg; Caitlin B Conboy; Ayano Kabashima; Daniel R O'Brien; Chen Wang; Sumera Rizvi; Rory L Smoot
Journal:  Mol Cancer Res       Date:  2020-07-09       Impact factor: 5.852

Review 8.  Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis.

Authors:  Sachin H Patel; Fernando D Camargo; Dean Yimlamai
Journal:  Gastroenterology       Date:  2016-12-19       Impact factor: 22.682

9.  PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells.

Authors:  Chen Chen; Dinghua Yang; Qinghua Zeng; Liang Luo; Chengzhi Cai
Journal:  Exp Ther Med       Date:  2018-03-20       Impact factor: 2.447

10.  Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans.

Authors:  Shanshan Zhang; Jingxiao Wang; Haichuan Wang; Lingling Fan; Biao Fan; Billy Zeng; Junyan Tao; Xiaolei Li; Li Che; Antonio Cigliano; Silvia Ribback; Frank Dombrowski; Bin Chen; Wenming Cong; Lixin Wei; Diego F Calvisi; Xin Chen
Journal:  Am J Pathol       Date:  2018-01-31       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.